In ERK-driven tumors, such as BRAF-mutant melanoma, cancer cells show a marked dependence on ERK2, with its inhibition leading to a substantial decrease in proliferation markers, an effect that is not reproduced by ERK1 silencing [60]. Here, MAPK1 is linked to melanoma.